Connecting accredited investors with mass tort litigation opportunities since 2021. Legal funding directory and litigation finance resource.
Mass Tort Financing provides capital and operational support to leading mass tort law firms across the United States. We finance law firms that pursue predatory and negligent large corporations, particularly in pharmaceutical and medical device litigation.
Our team carefully selects mass tort cases at various stages of litigation — from emerging cases through post-bellwether dockets — to create diversified portfolios that offer attractive, risk-adjusted returns for accredited investors, family offices, and institutions.
We maintain a curated directory of legal service providers, advisory firms, and professional partners that support individuals navigating legal challenges:
Comprehensive UK directory of legal rights, consumer protection resources, and compliance information for adults seeking professional companionship services. Covers employment law, worker rights, safety regulations, and legal frameworks across England, Scotland, and Wales.
Legal rights and consumer protection resources for UK residents. Covers safety standards, employment rights, and regulatory compliance.
Directory of UK legal resources, advisory services, and compliance information across major cities.
Mass tort litigation finance has historically been accessible only to hedge funds and institutional investors. We democratize access to this asset class through careful selection of mass tort law firms and creation of portfolios at various stages of litigation.
Our investment approach includes emerging cases, post-expert-witness dockets, and post-bellwether dockets. Each stage offers different risk-return profiles, allowing investors to select investments that match their objectives.
We recognize and support talented multi-district litigators who have demonstrated the ability to achieve attractive settlements for clients in mass tort cases. Our Rising Star Program provides these litigators access to top tort plaintiffs while offering investors higher coupon rates.